NASDAQ:CBLI - Cleveland BioLabs Stock Price, Forecast & News

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

Cleveland BioLabs, Inc. (NASDAQ:CBLI) released its quarterly earnings data on Thursday, November, 14th. The biotechnology company reported ($0.04) earnings per share for the quarter. The biotechnology company earned $0.27 million during the quarter. Cleveland BioLabs had a negative return on equity of 93.20% and a negative net margin of 241.79%. View Cleveland BioLabs' Earnings History.

Cleveland BioLabs is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Cleveland BioLabs.

Media headlines about CBLI stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cleveland BioLabs earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Cleveland BioLabs.

Cleveland BioLabs saw a decrease in short interest in the month of November. As of November 15th, there was short interest totalling 21,700 shares, a decrease of 13.5% from the October 31st total of 25,100 shares. Based on an average trading volume of 14,100 shares, the short-interest ratio is presently 1.5 days. Currently, 0.5% of the shares of the company are sold short. View Cleveland BioLabs' Current Options Chain.

Some companies that are related to Cleveland BioLabs include HedgePath Pharmaceuticals (HPPI), Tenax Therapeutics (TENX), Vitality Biopharma (VBIO), US Stem Cell (USRM), Geovax Labs (GOVX), Protalex (PRTX), ALGAE TEC LTD/S (ALGXY) and Redpoint Bio (RPBC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cleveland BioLabs investors own include Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), AVEO Pharmaceuticals (AVEO), Cidara Therapeutics (CDTX) and Concert Pharmaceuticals (CNCE).

Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBLI stock can currently be purchased for approximately $0.66.

Cleveland BioLabs has a market capitalization of $7.46 million and generates $1.14 million in revenue each year. View Additional Information About Cleveland BioLabs.

The official website for Cleveland BioLabs is http://www.cbiolabs.com/.

Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]